Multiple Myeloma: Advances in Diagnosis and Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 25 January 2025 | Viewed by 75

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Internal Medicine, Clinic Hirslanden Zurich, 8032 Zurich, Switzerland
2. Faculty of Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland
Interests: multiple myeloma; bood and marrow transplantation; hematology; hematopoietic cell transplantation; Waldenström’s macroglobulinemia; AL amyloidosis; liver cancer; meta-analysis; immunotherapy

Special Issue Information

Dear Colleagues,

Multiple myeloma is characterized as a complex hematological malignancy with abnormal plasma cell proliferation. During the last decade, remarkable advances in the diagnosis and treatment of multiple myeloma have been made. Due to increased understandings of the pathogensis of multiple myeloma, including clonal evolution, its microenviroment, the role of circulating cells and the innovation of diagnostic techniques, significant developments in detecting and monitoring multiple myeloma could be observed in the near future. Though advances in multiple myeloma could be achieved and translated into improved patients outcomes, ongoing research efforts are focusing on the treatment of relapsed/refractory multiple myeloma patients to explore novel therapeutic agents such as chimeric antigen reseptor (CAR), T-cell therapy, or bispecific T-cell engager (BiTE) treatment modalities and their mechanisms of resistance. In parallel, the exploration of non-immune therapy options in replased/refactory multiple myeloma and combination therapies to optimize therapy efficacy and adverse effects will hopefully expand the availability of therapies for multiple myeloma patients. Not only the treatment of refractory/relapsed myeloma, but also the extent to which precursor conditions such as MGUS or smoldering myeloma need to be treated, are topics for further analysis, which could greatly improve the current landscape of plasma cell dyscrasias.

We look forward to receiving your submissions.

Dr. Martina Kleber
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiple myeloma
  • early intervention
  • novel therapies
  • treatment approach
  • prognosis
  • bispecific antibodies
  • CAR T-cells

Published Papers

This special issue is now open for submission.
Back to TopTop